Incyte Corporation (INCY) |
|
59.33 -1.04 (-1.72%)
|
09-21 12:50 |
|
Open: |
60.24 |
Pre. Close: |
60.37 |
|
High:
|
60.38 |
Low:
|
59.1 |
|
Volume:
|
819,010 |
Market Cap:
|
13,295(M) |
|
|
|
Technical analysis |
as of: 2023-09-21 12:17:25 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 73.47  One year: 76.63 |
| Support: |
Support1: 58.54 Support2: 48.7 |
| Resistance: |
Resistance1: 62.9 Resistance2: 65.61 |
| Pivot: |
62.7 |
| Moving Average: |
MA(5): 60.45 MA(20): 63.16
MA(100): 63.56 MA(250): 71.34 |
| MACD: |
MACD(12,26): -1.1 Signal(9): -0.6 |
| Stochastic oscillator: |
%K(14,3): 22 %D(3): 19.9 |
| RSI: |
RSI(14): 31.2 |
| 52-week: |
High: 86.29 Low: 58.54 |
| Average Vol(K): |
3-Month: 1,523 (K) 10-Days: 1,932 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ INCY ] has closed above bottom band by 1.8%. Bollinger Bands are 50.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
61.08 - 61.37 |
61.37 - 61.67 |
|
Low:
|
59.41 - 59.79 |
59.79 - 60.16 |
|
Close:
|
59.67 - 60.27 |
60.27 - 60.86 |
|
Company Description |
|
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. |
Headline News |
Wed, 20 Sep 2023
Incyte Co. Reports Strong Second Quarter Earnings and Increased ... - Best Stocks
Tue, 19 Sep 2023
How Does Incyte Corporation (INCY) Stock Rank on Wall Street Tuesday? - InvestorsObserver
Tue, 19 Sep 2023
Pancreatic Cancer Battle Boosted by $200M VC Firm - Incyte (NASDAQ:INCY), BioNTech (NASDAQ:BNTX) - Benzinga
Tue, 19 Sep 2023
Incyte (INCY) Down on FDA Nod for Another Myelofibrosis Drug - Nasdaq
Mon, 18 Sep 2023
Anemia Advantage For GSK's Blood Cancer Therapy Could ... - Investing.com UK
Mon, 18 Sep 2023
Relative Strength Alert For Incyte - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
223 (M) |
| Shares Float |
187 (M) |
|
% Held by Insiders
|
1.4 (%) |
|
% Held by Institutions
|
99.4 (%) |
|
Shares Short
|
5,950 (K) |
|
Shares Short P.Month
|
5,730 (K) |
Stock Financials |
|
EPS
|
1.63 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
21.22 |
|
Profit Margin (%)
|
10.4 |
|
Operating Margin (%)
|
12.7 |
|
Return on Assets (ttm)
|
4.8 |
|
Return on Equity (ttm)
|
8.3 |
|
Qtrly Rev. Growth
|
4.6 |
|
Gross Profit (p.s.)
|
7.12 |
|
Sales Per Share
|
15.73 |
|
EBITDA (p.s.)
|
2.34 |
|
Qtrly Earnings Growth
|
25 |
|
Operating Cash Flow
|
781 (M) |
|
Levered Free Cash Flow
|
739 (M) |
Stock Valuations |
|
PE Ratio
|
36.13 |
|
PEG Ratio
|
1.2 |
|
Price to Book value
|
2.79 |
|
Price to Sales
|
3.76 |
|
Price to Cash Flow
|
16.92 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
